Literature DB >> 27157323

Comparative Evaluation of Four Real-Time PCR Methods for the Quantitative Detection of Epstein-Barr Virus from Whole Blood Specimens.

Daelynn Buelow1, Yilun Sun2, Li Tang2, Zhengming Gu1, Stanley Pounds2, Randall Hayden3.   

Abstract

Monitoring of Epstein-Barr virus (EBV) load in immunocompromised patients has become integral to their care. An increasing number of reagents are available for quantitative detection of EBV; however, there are little published comparative data. Four real-time PCR systems (one using laboratory-developed reagents and three using analyte-specific reagents) were compared with one another for detection of EBV from whole blood. Whole blood specimens seeded with EBV were used to determine quantitative linearity, analytical measurement range, lower limit of detection, and CV for each assay. Retrospective testing of 198 clinical samples was performed in parallel with all methods; results were compared to determine relative quantitative and qualitative performance. All assays showed similar performance. No significant difference was found in limit of detection (3.12-3.49 log10 copies/mL; P = 0.37). A strong qualitative correlation was seen with all assays that used clinical samples (positive detection rates of 89.5%-95.8%). Quantitative correlation of clinical samples across assays was also seen in pairwise regression analysis, with R(2) ranging from 0.83 to 0.95. Normalizing clinical sample results to IU/mL did not alter the quantitative correlation between assays. Quantitative EBV detection by real-time PCR can be performed over a wide linear dynamic range, using three different commercially available reagents and laboratory-developed methods. EBV was detected with comparable sensitivity and quantitative correlation for all assays.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27157323      PMCID: PMC5818632          DOI: 10.1016/j.jmoldx.2016.02.002

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  18 in total

1.  Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation.

Authors:  Y Hoshino; H Kimura; N Tanaka; I Tsuge; K Kudo; K Horibe; K Kato; T Matsuyama; A Kikuta; S Kojima; T Morishima
Journal:  Br J Haematol       Date:  2001-10       Impact factor: 6.998

2.  Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

Authors:  J W van Esser; B van der Holt; E Meijer; H G Niesters; R Trenschel; S F Thijsen; A M van Loon; F Frassoni; A Bacigalupo; U W Schaefer; A D Osterhaus; J W Gratama; B Löwenberg; L F Verdonck; J J Cornelissen
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

3.  Multicenter evaluation of a commercial cytomegalovirus quantitative standard: effects of commutability on interlaboratory concordance.

Authors:  R T Hayden; M D Shahbazian; A Valsamakis; J Boonyaratanakornkit; L Cook; X L Pang; J K Preiksaitis; E R Schönbrunner; A M Caliendo
Journal:  J Clin Microbiol       Date:  2013-09-11       Impact factor: 5.948

Review 4.  Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease.

Authors:  Hiroshi Kimura; Yoshinori Ito; Ritsuro Suzuki; Yukihiro Nishiyama
Journal:  Rev Med Virol       Date:  2008 Sep-Oct       Impact factor: 6.989

5.  Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.

Authors:  A Gustafsson; V Levitsky; J Z Zou; T Frisan; T Dalianis; P Ljungman; O Ringden; J Winiarski; I Ernberg; M G Masucci
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

6.  Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response.

Authors:  J Yang; Q Tao; I W Flinn; P G Murray; L E Post; H Ma; S Piantadosi; M A Caligiuri; R F Ambinder
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

7.  Multicenter comparison of different real-time PCR assays for quantitative detection of Epstein-Barr virus.

Authors:  R T Hayden; K M Hokanson; S B Pounds; M J Bankowski; S W Belzer; J Carr; D Diorio; M S Forman; Y Joshi; D Hillyard; R L Hodinka; M N Nikiforova; C A Romain; J Stevenson; A Valsamakis; H H Balfour
Journal:  J Clin Microbiol       Date:  2007-11-07       Impact factor: 5.948

8.  Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease.

Authors:  A Savoie; C Perpête; L Carpentier; J Joncas; C Alfieri
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

9.  Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.

Authors:  M Green; T V Cacciarelli; G V Mazariegos; L Sigurdsson; L Qu; D T Rowe; J Reyes
Journal:  Transplantation       Date:  1998-12-27       Impact factor: 4.939

10.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

View more
  4 in total

1.  A Comprehensive Statistical Framework for Determination of Commutability, Accuracy, and Agreement in Clinical DNAemia Assays.

Authors:  L Tang; Y Su; Z Gu; A M Caliendo; S Pounds; R T Hayden
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

2.  Quantitative Assessment of Commutability for Clinical Viral Load Testing Using a Digital PCR-Based Reference Standard.

Authors:  L Tang; Y Sun; D Buelow; Z Gu; A M Caliendo; S Pounds; R T Hayden
Journal:  J Clin Microbiol       Date:  2016-04-13       Impact factor: 5.948

Review 3.  Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer.

Authors:  Shyam Singh; Hem Chandra Jha
Journal:  J Oncol       Date:  2017-03-21       Impact factor: 4.375

4.  Automated Nucleic Acid Extraction Systems for Detecting Cytomegalovirus and Epstein-Barr Virus Using Real-Time PCR: A Comparison Study Between the QIAsymphony RGQ and QIAcube Systems.

Authors:  Hanah Kim; Mina Hur; Ji Young Kim; Hee Won Moon; Yeo Min Yun; Hyun Chan Cho
Journal:  Ann Lab Med       Date:  2017-03       Impact factor: 3.464

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.